Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)
Industry: PharmaceuticalsMajor

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Current Quote*
Last: $24.270
Change: 0.510
Book: $3.538
Volume: 29,751

As Of: 01/18 13:33 ET
*Quotes delayed by 20min.

Graphs for KNSA


3 Month Graph


6 Month Graph


1 Year Graph